These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 4650857)

  • 1. Treatment of muscular dystrophy.
    Bradley WG; Polgar JG; Williams MH; Boddie HG
    Br Med J; 1972 Sep; 3(5828):699-700. PubMed ID: 4650857
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon treatment for muscular dystrophy in the mouse.
    Pope RS
    Am J Physiol; 1973 Sep; 225(3):518-20. PubMed ID: 4726484
    [No Abstract]   [Full Text] [Related]  

  • 3. Glucagon treatment of muscular dystrophic mice: a lack of effect.
    Yen TT; Allan JA
    Experientia; 1974 Aug; 30(8):908. PubMed ID: 4413580
    [No Abstract]   [Full Text] [Related]  

  • 4. Is muscular dystrophy a primary myopathy?
    Pope RS
    Perspect Biol Med; 1975; 18(2):287-91. PubMed ID: 1196832
    [No Abstract]   [Full Text] [Related]  

  • 5. [Some indices of energy metabolism in the tissues of mice with progressive muscular dystrophy under the action of ubiquinone].
    Monakhov NK; Obol'nikova EA; Igdal LG; Torosian ZhK; Antelava NA
    Vopr Med Khim; 1974 May; 20(3):276-84. PubMed ID: 4275937
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of murine muscular dystrophy with the proteinase inhibitor leupeptin.
    Sher JH; Stracher A; Shafiq SA; Hardy-Stashin J
    Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7742-4. PubMed ID: 6950412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experimental animal information file: effect of bestatin in muscular dystrophy in mice].
    Kawamata J
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2425-6. PubMed ID: 6639104
    [No Abstract]   [Full Text] [Related]  

  • 8. Animal models of muscle diseases, Part III: Compilation of therapeutic trials for hereditary muscular dystrophy.
    Cosmos E; Butler J
    Muscle Nerve; 1980; 3(5):427-35. PubMed ID: 7421876
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic trials in muscular dystrophy. 1. Gold in murine dystrophy.
    Enomoto A; Bradley WG
    J Neurol Neurosurg Psychiatry; 1978 May; 41(5):404-7. PubMed ID: 96218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Animal models for muscular dystrophy--muscular dystrophy in mice].
    Tsuji S; Matsushita H
    Nihon Rinsho; 1977 Nov; 35(11):3936-42. PubMed ID: 340729
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of spider Latrodectus tredecimguttatus poison on progressive muscular dystrophy in rat.
    Stern P; Valjevac K; Gmaz-Nikulin E
    Arzneimittelforschung; 1975 May; 25(5):769-71. PubMed ID: 1242318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy.
    Lescop C; Herzner H; Siendt H; Bolliger R; Henneböhle M; Weyermann P; Briguet A; Courdier-Fruh I; Erb M; Foster M; Meier T; Magyar JP; von Sprecher A
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5176-81. PubMed ID: 16185867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of endurance of DMD animal model using natural polyphenols.
    Sitzia C; Farini A; Colleoni F; Fortunato F; Razini P; Erratico S; Tavelli A; Fabrizi F; Belicchi M; Meregalli M; Comi G; Torrente Y
    Biomed Res Int; 2015; 2015():680615. PubMed ID: 25861640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib partially improves laminin α2 chain-deficient muscular dystrophy.
    Körner Z; Fontes-Oliveira CC; Holmberg J; Carmignac V; Durbeej M
    Am J Pathol; 2014 May; 184(5):1518-28. PubMed ID: 24631023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine and Duchenne muscular dystrophy.
    Betorini TE; Horner LH; Nutting DF
    Neurology; 1994 Jun; 44(6):1190. PubMed ID: 8208432
    [No Abstract]   [Full Text] [Related]  

  • 17. Penicillamine treatment of hereditary avian muscular dystrophy.
    Chou TH; Hill EJ; Patnode R; LeQuire V; Roelofs R; Park JH
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):89-93. PubMed ID: 122684
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic trials in muscular dystrophy: II. Ethylene and its derivatives.
    Enomoto A; Bradley WG
    Ann Neurol; 1977 Oct; 2(4):267-70. PubMed ID: 617265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
    Lowe J; Floyd KT; Rastogi N; Schultz EJ; Chadwick JA; Swager SA; Zins JG; Kadakia FK; Smart S; Gomez-Sanchez EP; Gomez-Sanchez CE; Raman SV; Janssen PM; Rafael-Fortney JA
    J Neuromuscul Dis; 2016; 3(3):395-404. PubMed ID: 27822449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective activation of α7 nicotinic acetylcholine receptor (nAChRα7) inhibits muscular degeneration in mdx dystrophic mice.
    Leite PE; Gandía L; de Pascual R; Nanclares C; Colmena I; Santos WC; Lagrota-Candido J; Quirico-Santos T
    Brain Res; 2014 Jul; 1573():27-36. PubMed ID: 24833065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.